Table 4.
Multivariate Cox proportional hazards regression analysis for metastasis-free survival with prostate- specific antigen (PSA) bounce as time-dependent variable in 186 patients treated with EBRT combined with BT boost and ADT for localized prostate cancer
| Level | Parameter estimate | HR (95% CI) | p-value | |
|---|---|---|---|---|
| TNM | > T1c vs. T1c | 1.393 | 4.03 (1.01-16.05) | 0.048 |
| Gleason grade group | 3/4 vs. 1/2 | 0.783 | 2.19 (0.74-6.49) | 0.159 |
| 5 vs. 1/2 | 1.249 | 3.49 (1.29-9.47) | 0.014 | |
| Maximum PSA (ng/ml) | –0.027 | 0.97 (0.94-1.01) | 0.202 | |
| nPSA (10 ng/ml) | 0.118 | 1.13 (1.07-1.19) | < 0.001 | |
| PSA bounce (time-varying) | –1.606 | 0.20 (0.03-1.38) | 0.103 | |
Gleason grade group – International Society of Urological Pathology 2014 grade group system; nPSA – PSA nadir